OM:GENOLife Sciences
Genovis (OM:GENO) Margin Compression To 17.7% Tests Bullish Growth Narratives
Genovis AB (publ.) (OM:GENO) has wrapped up FY 2025 with fourth quarter revenue of 40.999 million SEK and basic EPS of 0.10 SEK, while the trailing twelve months show revenue of 132.945 million SEK and EPS of 0.36 SEK. These figures help set the tone for how the market will read the results. The company has seen quarterly revenue move from 28.9 million SEK in Q4 2024 to 40.999 million SEK in Q4 2025, with EPS over the same quarters shifting from 0.07 SEK to 0.10 SEK. Investors will be...